Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study shows FDA says raw images enrich the data when used with clinician assessments

Breaking barriers in lung cancer research

The fight against lung cancer is evolving, with groundbreaking research shedding light on the intricate interplay between biology, environment, and health disparities.

September 12, 2025

Vol.51 No.33

By Loretta Erhunmwunsee

Obituary

Bonnie Addario, lung cancer survivor and advocate, dies at 77

Bonnie J. Addario, a tireless advocate, died Aug. 25, leaving behind a legacy of love, leadership, and global impact. Bonnie was first and foremost devoted to her family—her husband of over 40 years, Tony; her children Danielle, Jared, and Andrea; her nine grandchildren; and five great-grandchildren. To all of them, she was the heart of...

September 12, 2025

Vol.51 No.33

By Neptune Society

Cancer Policy

Vinay Prasad regains role as FDA chief medical and scientific officer

Vinay Prasad has regained his role as FDA’s chief medical and scientific officer, according to an update on the agency’s website.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

Cancer Policy

FDA advances rare disease drug development with new evidence principles

FDA introduced the Rare Disease Evidence Principles to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

Montefiore Einstein’s lung cancer team earns international recognition

Montefiore Einstein CCC lung cancer teamMontefiore Einstein Comprehensive Cancer Center’s lung cancer team received the The Cancer Care Team Award from the International Association for the Study of Lung Cancer.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.

September 12, 2025

Vol.51 No.33

Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study shows

FDA says raw images enrich the data when used with clinician assessments

YOU MAY BE INTERESTED IN

Breaking barriers in lung cancer research

Bonnie Addario, lung cancer survivor and advocate, dies at 77

Vinay Prasad regains role as FDA chief medical and scientific officer

FDA advances rare disease drug development with new evidence principles

Montefiore Einstein’s lung cancer team earns international recognition

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login